The global veterinary rapid test market is estimated to be worth USD 942.3 million by 2024 and is projected to reach a value of USD 2870 million by 2034. Over the projection period, global demand for veterinary rapid tests is predicted to increase at a CAGR of 11.8%.
The veterinary rapid test industry is set to experience profitable growth during the forecast period. The sector is projected to create an incremental opportunity of USD 1927.7 million through 2034 owing to growing prevalence of veterinary diseases.
Preventive healthcare is becoming increasingly important, as early detection of diseases leads to more effective and cost-efficient treatments. Rapid tests help provide results within minutes to hours, enabling veterinarians and animal owners to make timely decisions for pet treatment and management.
Several companies are launching new products with unique features to compete in the sector. For instance, in 2023, Zoetis introduced Vetscan Mastigram+, a rapid on-farm diagnostic test kit for mastitis.
Several factors are projected to stimulate growth of the industry during the forecast period. These include increasing animal population, focus on preventive healthcare, biotechnological developments in veterinary diagnosis tests, and adoption of pet insurance.
Technological developments in biotechnology and diagnostic technologies spur innovation, improve diagnostic accuracy, and enhance the performance of diagnostic tools. Furthermore, the growing trend of pet ownership and humanization has led to a surging focus on pet health and well-being.
Pet owners are investing in healthcare measures, including preventive health awareness and regular health screenings using veterinary rapid tests. Veterinary clinics and healthcare providers are providing comprehensive wellness programs for pets to assess health and detect potential issues early, propelling sales.
Veterinary rapid tests, including multiplexing and panel testing, are gaining traction for high efficiency in detecting multiple pathogens in a single sample. Integration of digital solutions is improving veterinary rapid tests by enhancing workflow efficiency and enabling real-time data sharing. For instance, in 2023, Gold Standard Diagnostics launched four new diagnostic test kits under Simplex DNAnimal kits for veterinary use.
Regulations and new policies significantly influence the global market by ensuring product efficiency, safety, and quality standards. Governments are implementing preventive healthcare programs like vaccination campaigns and biosecurity measures to reduce viral disease spread, propelling growth.
Manufacturers are intensifying competition to enhance product lines, offering unique features, and value propositions, resulting in a wide range of high-quality diagnostic options. For instance, in 2023, BioStone Animal Health introduced the AsurDx Japanese Encephalitis (JEV) Antibody Test Kit, specifically designed to identify pig antibodies against the virus.
Attributes | Description |
---|---|
Estimated Global Veterinary Rapid Test Market Size (2024E) | USD 942.3 million |
Projected Global Veterinary Rapid Test Market Value (2034F) | USD 2870 million |
Value-based CAGR (2024 to 2034) | 11.8% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Increasing Incidence of Zoonotic Diseases
The market is projected to rise at a substantial CAGR through 2034. This growth is attributed to progressions in diagnostic technology, including point-of-care testing and molecular diagnostics, boosting the adoption of veterinary diagnostics.
Rising prevalence of zoonotic disease incidences and increasing investments by governments and welfare associations worldwide is anticipated to accelerate growth. The market is further projected to see a positive outlook due to the high prevalence of urinary tract infections (UTIs) among pets, fueling demand for rapid tests.
Point-of-care-Testing to Propel Sales
Inclination towards developing species-specific tests tailored to different animal species is anticipated to augment demand. These tests allow for optimization of test performance, which is spurring growth. Point-of-care testing (POCT) is gaining traction for on-site diagnostics and immediate results, making it more valuable for practitioners and pet owners.
Rising Application in Veterinary Medicine
Rapid diagnostic tests in the veterinary healthcare sector are gaining momentum due to the quick and accurate disease-detection ability. Progressions in diagnostic technology, such as lateral flow assays, immunochromatography, and nucleic acid amplification, are enhancing the reliability of veterinary rapid tests. These tests are set to be vital for disease surveillance, control, and early intervention in veterinary populations.
For instance, in 2023, Basepaws, headquartered in California, launched a DNA test for dogs. The company’s focus is on accelerating health genetic testing and promoting proactive pet care through an easy swabbing procedure.
Lack of Awareness to Impede Growth
Rising cost of animal healthcare worldwide is set to hinder growth. Limited infrastructures for veterinary diagnosis and lack of awareness are the key factors projected to impede development.
The worldwide veterinary rapid test sales grew at a noteworthy CAGR of 15.3% during the historical period between 2019 and 2023. Market growth of veterinary rapid tests was positive, as it reached a value of USD 820.8 million in 2023.
Veterinary rapid tests were primarily utilized by veterinary clinics and hospitals. From 2019 to 2023, the industry surged to include research institutions, livestock producers, and regulatory agencies for rapid animal health monitoring and surveillance.
Developments in diagnostic technology, such as lateral flow immunoassays and fluorescence-based detection systems, have made rapid testing more accessible and practical for veterinarians. From 2019 to 2023, demand for veterinary rapid tests in disease outbreak response surged, enabling early detection, containment, and control of infectious diseases.
By 2034, the sector is projected to rise at a bit sluggish CAGR of 11.8%. The increasing prevalence of transboundary diseases and emerging pathogens is projected to fuel demand for rapid diagnostic solutions.
Rapid diagnostic tests for dogs, cats, and other pets are gaining momentum as the role of pets in homes changed and pet healthcare programs advanced. Manufacturers are enhancing sensitivity and specificity through improved detection methods, optimized designs, and controls to minimize false-positive and false-negative results.
The section below highlights opportunities available in different countries of North America, Europe, and South Asia. It also shows the veterinary rapid test industry size in a graphical presentation in leading countries. The section highlights key strategies adopted by several companies to meet the demand for veterinary rapid tests in overseas markets.
The report provides detailed information about the Europe veterinary rapid test industry size and share. The United Kingdom is set to surge at 13.1% CAGR by 2034. On the other hand, emerging nations like China are set to take over the spotlight, recording high CAGRs.
Growing attention towards livestock animals’ health and disease prevention are set to create opportunities in North America. The United States is anticipated to remain at the forefront in North America, with a CAGR of 12.1% through 2034.
Countries | CAGR 2024 to 2034 |
---|---|
United States | 12.1% |
United Kingdom | 13.1% |
China | 12.6% |
South Korea | 14.1% |
Japan | 13.6% |
The United States veterinary rapid test industry is poised to exhibit a CAGR of 12.1% during the assessment period. By 2034, the sector is projected to reach USD 511.4 million. Rising usage of diagnostic testing as a result of widespread pet insurance coverage is a leading factor fueling growth in the United States.
Growing prevalence of illnesses that are reportable among livestock, such as avian influenza, bovine TB, and chronic disease, have led to a requirement for accurate and timely diagnosis. The demand for early illness detection, especially in light of the increased frequency of diseases, is set to contribute to growth.
China’s veterinary rapid test sector is growing rapidly, propelled by several factors. Rising middle-class families and high pet ownership are set to create ample opportunities for manufacturers. The industry is anticipated to increase at a steady CAGR of 12.6% during the forecast period.
According to a report, in China, there are 51 million pet dogs and 65 million pet cats, with one in eight citizens owning a pet. The sector is further propelled by the issue of infectious diseases in beef cattle, emphasizing the necessity of trained professionals for effective disease management.
Japan's veterinary rapid test market is projected to reach USD 320.2 million by 2034. This growth is attributed to the improvement of diagnostic test kits. The sector is set to rise at 13.6% CAGR by 2034, owing to favorable government initiatives, increasing artificial insemination, and a high livestock population.
Japan's adoption of pets and breeding techniques in livestock production is projected to propel the market. Rising emphasis on broiler farms and the adoption of bovine artificial insemination procedures are further set to fuel growth.
The section below throws some light on leading segments along with the estimated growth rates. This information can be essential for key companies to assess different segments and the impact on growth.
In terms of product, the rapid test kit segment accounted for a share of 73% in 2023. This is due to its importance in making the veterinary disease test faster, easier, and more efficient. Based on end-users, the veterinary hospitals and clinics segment is set to dominate the industry, accounting for a 65% share in 2023.
Segment | Rapid Test Kits (Product) |
---|---|
Value Share (2023) | 73% |
Based on the product, rapid test kits are projected to lead the sector during the forecast period. These are anticipated to rise at a CAGR of 11.6% by 2034.
Technological progressions in veterinary diagnostics have led to the development of accurate, sensitive, and rapid diagnostic test kits such as PCR, ELISA, and lateral flow assays. These innovations enhance efficiency and effectiveness, stimulating growth.
Leading companies and manufacturers are continuously introducing new veterinary rapid diagnostic test kits, addressing emerging needs in veterinary medicine. This includes detecting novel pathogens or monitoring health parameters, which contributes to development. Demand for rapid test kits is projected to remain high during the forecast period.
Segment | Veterinary Hospitals and Clinics (End-user) |
---|---|
Value Share (2023) | 65% |
Based on end-users, the veterinary hospitals and clinics segment is set to rise at 11.4% CAGR by 2034. With a revenue share of 65% in 2023, the segment led the market. This growth is attributed to the rising need for diagnostics and easily available quick diagnostic instruments in veterinary clinics and hospitals.
Veterinary hospitals and clinics play a significant role in informing pet owners about the importance of diagnostics in maintaining animals' health. The end-user further encourages pet owners to seek diagnostic test kits when needed by raising awareness about the issue.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Leading manufacturers are constantly enhancing presence in the market by introducing innovative products, partnering with other start-ups, and entering into new regions. The key focus is on seeking collaborative strategies to broaden industry share, extend product portfolios, and acquire emerging technologies. The industry is highly fragmented due to the presence of numerous global and regional companies.
Zoetis, IDEXX Laboratories, Inc., Virbac, Heska Corporation, and Thermo Fisher Scientific, Inc. are the leading veterinary rapid test companies functioning in the industry. Mergers and acquisitions are common growth strategies. Stakeholders are continuously working on improving veterinary diagnostics through research and development. These strategies are set to heighten the competitive and dynamic atmosphere of the market.
Industry Updates
The industry includes two leading products, namely, rapid test kits and rapid test readers.
The leading testing categories are virology, parasitology, bacteriology, clinical chemistry, and others.
Prominent technologies in the industry include immunoassays and PCR.
In terms of animal type, the report is bifurcated into companion animals and production animals. To get a broad view of the sector, the companion animal category is further classified into dogs, cats, horses, and others, and production animals into cattle, poultry, swine, and others.
Key end-users in the industry are veterinary hospitals and clinics, home care settings, and others.
Analysis of the target industry has been carried out in key countries of North America, Latin America, Western Europe, South Asia, East Asia, Eastern Europe, and the Middle East and Africa.
The industry is set to reach USD 942.3 million in 2024.
Demand for veterinary rapid tests is slated to rise at an 11.8% CAGR by 2034.
The industry is projected to reach USD 2870 million in 2034.
Zoetis, IDEXX Laboratories, Inc., Virbac, and Heska Corporation.
The rapid test kits segment is estimated to hold a significant share in 2024.
Veterinary hospitals and clinics are set to dominate by 2034.
1. Executive Summary
2. Industry Introduction, including Taxonomy and Market Definition
3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections
5. Pricing Analysis
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034
6.1. Product
6.2. Testing Category
6.3. Technology
6.4. Animal Type
6.5. End User
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product
7.1. Rapid Test Kits
7.2. Rapid Test Readers
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Testing Category
8.1. Virology
8.2. Parasitology
8.3. Bacteriology
8.4. Clinical Chemistry
8.5. Others
9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Technology
9.1. Immunoassays
9.2. PCR
10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Animal Type
10.1. Companion Animal
10.1.1. Dogs
10.1.2. Cats
10.1.3. Horses
10.1.4. Others
10.2. Production Animal
10.2.1. Cattle
10.2.2. Poultry
10.2.3. Swine
10.2.4. Others
11. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End User
11.1. Veterinary Hospitals & Clinics
11.2. Homecare Settings
11.3. Others
12. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
12.1. North America
12.2. Latin America
12.3. Western Europe
12.4. South Asia
12.5. East Asia
12.6. Eastern Europe
12.7. Middle East & Africa
13. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
14. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
15. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
16. South Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
17. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
18. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
19. Middle East & Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
20. Sales Forecast 2024 to 2034 by Product, Testing Category, Technology, Animal Type, and End User for 30 Countries
21. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
22. Company Profile
22.1. Zoetis
22.2. IDEXX Laboratories, Inc.
22.3. Virbac
22.4. Heska Corporation
22.5. Thermo Fisher Scientific, Inc.
22.6. Neogen Corporation
22.7. Prometheus Bio Inc.
22.8. Fassisi GmbH
22.9. Biopanda Reagents Ltd
22.10. Boster Biological Technology
Explore Healthcare Insights
View Reports